| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000041162 |
| Receipt No. | R000046826 |
| Scientific Title | Effect of Daily Ingestion of the tea powder on improving physical-mental minor complaints: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study |
| Date of disclosure of the study information | 2020/07/27 |
| Last modified on | 2021/04/15 (Ver. 3) |
| Basic information | ||
| Public title | Effect of Daily Ingestion of the tea powder on improving physical-mental minor complaints: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study | |
| Acronym | Beneficial effect of the tea powder on improving physical-mental minor complaints | |
| Scientific Title | Effect of Daily Ingestion of the tea powder on improving physical-mental minor complaints: A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Comparison Study | |
| Scientific Title:Acronym | Beneficial effect of the tea powder on improving physical-mental minor complaints | |
| Region |
|
|
| Condition | |||
| Condition | Healthy adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | To prove improving physical-mental minor complaints and safety associated with 8 weeks daily ingestion of the tea powder, in a double-blind, placebo-controlled, parallel group comparison study. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Peripheral blood test after 8 weeks of ingestion. |
| Key secondary outcomes | Questionnaire about subjects' background information, Electroencephalogram during sleeping, Sleeping record, Heart rate variability, Intestinal flora, VAS questionnaire assessed fatigue. |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | NO |
| Institution consideration | |
| Blocking | |
| Concealment | No need to know |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Prevention | |
| Type of intervention |
|
|
| Interventions/Control_1 | Daily ingestion 3 g of the tea-1 for 8 weeks. | |
| Interventions/Control_2 | Daily ingestion 3 g of the tea-2 for 8 weeks. | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Subjects who agree to participate in this study with a written informed consent.
2. Subjects with physical-mental minor complaints. |
|||
| Key exclusion criteria | 1. Subjects who participated in UMIN000038876.
2. Subjects with serious cerebrovascular, cardiac, hepatic, renal, gastrointestinal diseases, and/or affected with infectious diseases requiring reports to the authorities. 3. Subjects with major surgical history relevant to the digestive system such as gastrectomy, gastrorrhaphy, enterectomy, etc. 4. Subjects with unusually high and/or low blood pressure and/or abnormal hematological data. 5. Subjects with severe anemia. 6. Pre- or post-menopausal women complaining of obvious physical changes. 7. Subjects who are at risk of having allergic reactions to drugs or foods especially based on tea. 8. Subjects who has high caffeine sensitivity. 9. Subjects who regularly take medicine, functional foods, and/or supplements which would affect sleep and/or stress. 10. Heavy smokers, alcohol addicts or subjects with disordered lifestyle. 11. Subjects who donated either 400 ml whole blood within 16 weeks (women), 12 weeks (men), 200 ml whole blood within 4 weeks (men and women), or blood components within 2 weeks (men and women), prior to the current study. 12. Pregnant or lactating women or women who expect to be pregnant during this study. 13. Subjects who currently participate in other clinical trials, or participated within the last 4 weeks prior to the current study. 14. Any other medical and/or health reasons unfavorable to participation in the current study, as judged by the principal investigator. |
|||
| Target sample size | 16 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Hokkaido Information University | ||||||
| Division name | Department of Medical Management and Informatics | ||||||
| Zip code | 069-8585 | ||||||
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan | ||||||
| TEL | 011-385-4411 | ||||||
| nishihira@do-johodai.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Hokkaido Information University | ||||||
| Division name | Health Information Science Center | ||||||
| Zip code | 069-8585 | ||||||
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan | ||||||
| TEL | 011-385-4430 | ||||||
| Homepage URL | |||||||
| nishihira@do-johodai.ac.jp | |||||||
| Sponsor | |
| Institute | Hokkaido Information University |
| Institute | |
| Department | |
| Funding Source | |
| Organization | National Agriculture and Food Research Organization, bio-oriented technology Research Advancement Institution |
| Organization | |
| Division | |
| Category of Funding Organization | Japanese Governmental office |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Sapporo Medical University, National Agriculture and Food Research Organization |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | The ethics committee of Hokkaido Information University |
| Address | 59-2, Nishi-nopporo, Ebetsu, Hokkaido, 069-8585, Japan |
| Tel | 011-385-4411 |
| soumu@do-johodai.ac.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 北海道情報大学 保健センター(北海道) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000046826 |